Cybin, Inc. Company Profile
CYBN Stock Chart
CYBN News
- Cybin Announces Additional Adelia Milestone Achievement
- Cybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022
- Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021
- Cybin to Present at the Emerging Growth Conference on June 23rd
- Cybin to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th
- Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy
- Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms
- Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder
- Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003
- Cybin Demonstrates Proof of Concept of Its Deuterated Tryptamines for the Treatment of Depression and Addiction
Investor Information
Investor Presentation
Cannacord Genuity Research Report
Stifel GMP Reasarch Report
